← Back to Search

Antibiotic

Rifaximin for Weight Loss

Phase 4
Waitlist Available
Led By Bhavin Dave, MD
Research Sponsored by Bayhealth Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
BMI of 30-35
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline lipid results at 6 months
Awards & highlights

Study Summary

Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet

Eligible Conditions
  • Weight Loss

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline weight at 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline weight at 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
BMI
Weight loss
Secondary outcome measures
HbA1C
Lipids

Side effects data

From 2014 Phase 4 trial • 222 Patients • NCT01842581
19%
Hepatic encephalopathy
17%
Oedema peripheral
16%
Constipation
14%
Nausea
14%
Fatigue
12%
Insomnia
11%
Urinary tract infection
10%
Pruritus generalised
8%
Muscle spasms
7%
Abdominal pain
7%
Decreased appetite
6%
Ascites
6%
Dyspnoea
6%
Headache
5%
Cough
5%
Renal failure acute
5%
Vomiting
5%
Asthenia
5%
Anaemia
5%
Anxiety
4%
Jaundice
4%
Diarrhoea
3%
Abdominal distension
3%
Cellulitis
3%
Depression
2%
Bronchitis
2%
Peritonitis bacterial
2%
Hyperkalaemia
2%
Liver transplant
1%
Gastrointestinal haemorrhage
1%
Acute respiratory failure
1%
Haematemesis
1%
Hyperglycaemia
1%
Fluid overload
1%
Non-cardiac chest pain
1%
Herpes zoster
1%
Cerebrovascular accident
1%
Thrombocytopenia
1%
Pneumococcal bacteraemia
1%
Pneumonia
1%
Sepsis
1%
Septic shock
1%
Craniocerebral injury
1%
Hepatic failure
1%
Hepatitis
1%
Hepatorenal syndrome
1%
Toxic encephalopathy
1%
Subarachnoid haemorrhage
1%
Anxiety disorder
1%
Suicidal ideation
1%
Calculus ureteric
1%
Oliguria
1%
Renal failure
1%
Pleural effusion
1%
Flatulence
1%
Cardiac failure congestive
1%
Haematochezia
1%
Upper gastrointestinal haemorrhage
1%
Chest pain
1%
Systemic inflammatory response syndrome
1%
Chronic hepatic failure
1%
Subdural haematoma
1%
Dehydration
1%
Alcoholic seizure
1%
Hypovolaemic shock
100%
80%
60%
40%
20%
0%
Study treatment Arm
Rifaximin 550 mg BID
Rifaximin 550 mg BID + Lactulose

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Rifaxamin (R)Experimental Treatment1 Intervention
Patients in the experimental group will receive additional instructions to take 550 mg of Rifaximin 3 times a day for 12 days at the start of the diet. The experimental group will be provided the required doses of Rifaximin at the initial weigh-in and office visit.
Group II: ControlActive Control1 Intervention
Participants in the control group will undergo no intervention and will only be asked to follow an Intermittent fasting diet.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rifaximin
FDA approved

Find a Location

Who is running the clinical trial?

Bayhealth Medical CenterLead Sponsor
Bhavin Dave, MDPrincipal InvestigatorBayhealth Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Journal of GastroenterologyJournal
The Role of Small Intestinal Bacterial Overgrowth in Cystic Fibrosis: A Randomized Case-controlled Clinical Trial with Rifaximin
Furnari, Manuele, Alessandra De Alessandri, Federico Cresta, Maria Haupt, Marta Bassi, Angela Calvi, Riccardo Haupt, et al.. 2018. “The Role of Small Intestinal Bacterial Overgrowth in Cystic Fibrosis: A Randomized Case-controlled Clinical Trial with Rifaximin”. Journal of Gastroenterology. Springer Science and Business Media LLC. doi:10.1007/s00535-018-1509-4.
clinicaltrials.govStudy
Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet
Bhavin Dave, MD 2021. "Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04674176.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top